Therefore, therapeutic interference with the IL-17 axis seems to be a feasible and promising research and therapeutic approach, especially considering the fact that tumor suppressor molecules in MM, such as MiR-15a/16, inhibit myelomagenesis, among others, by reducing IL-17 expression [69]. The gene discussed is IL17A; the disease is Miyoshi myopathy.